<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOLTERODINE TARTRATE- tolterodine tartrateÂ tablet, film coatedÂ </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_e54b2025-e5f1-46fe-b3ef-bf131f09904b"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Tolterodine tartrate tablets contain tolterodine tartrate. The active moiety, tolterodine, is a muscarinic receptor antagonist. The chemical name of tolterodine tartrate is (+)-(<span class="Italics">R</span>)-2-[I-[2-(Diisopropylamino)ethyl]benzyl]-<span class="Italics">p</span>-cresol L-tartrate (1:1) (salt). The molecular formula of tolterodine tartrate is C<span class="Sub">26</span>H<span class="Sub">37</span>NO<span class="Sub">7</span>, and its molecular weight is 475.6. The structural formula of tolterodine tartrate is represented below: </p>
<div class="Figure"><img alt="Tolterodine Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=304023e8-57ad-4dd7-9cf0-a4524623aa6c&amp;name=bfc370b4-6a62-44de-a353-dd59768e3133-01.jpg"></div>
<p> Tolterodine tartrate is a white to off-white colored solid. The pK<span class="Sub">a</span> value is 9.87 and the solubility in water is 12 mg/mL. It is soluble in methanol, slightly soluble in ethanol, and practically insoluble in toluene. The partition coefficient (Log D) between n-octanol and water is 1.83 at pH 7.3. </p>
<p> Tolterodine tartrate tablets for oral administration contain 1 mg or 2 mg of tolterodine tartrate. The inactive ingredients are colloidal silicon dioxide, dibasic calcium phosphate, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate, titanium dioxide and triacetin. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_317c09bc-3c04-4c96-ae71-ea9ed6c352ff"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> are mediated via cholinergic muscarinic receptors. </p>
<p> After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl derivative, a major pharmacologically active metabolite. The 5-hydroxymethyl metabolite, which exhibits an antimuscarinic activity similar to that of tolterodine, contributes significantly to the therapeutic effect. Both tolterodine and the 5-hydroxymethyl metabolite exhibit a high specificity for muscarinic receptors, since both show negligible activity or affinity for other neurotransmitter receptors and other potential cellular targets, such as calcium channels. </p>
<p> Tolterodine has a pronounced effect on bladder function. Effects on urodynamic parameters before and 1 and 5 hours after a single 6.4 mg dose of tolterodine immediate-release were determined in healthy volunteers. The main effects of tolterodine at 1 and 5 hours were an increase in residual urine, reflecting an incomplete emptying of the bladder, and a decrease in detrusor pressure. These findings are consistent with an antimuscarinic action on the lower urinary tract. </p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9e46d53e-ece6-40ac-a8b4-d44dabeecd52"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_585d1079-3598-4cbf-bc51-a6c922ed1b7f"></a><a name="section-2.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">In a study with <span class="Sup">14</span>C-tolterodine solution in healthy volunteers who received a 5 mg oral dose, at least 77% of the radiolabeled dose was absorbed. Tolterodine immediate-release is rapidly absorbed, and maximum serum concentrations (C<span class="Sub">max</span>) typically occur within 1 to 2 hours after dose administration. C<span class="Sub">max</span> and area under the concentration-time curve (AUC) determined after dosage of tolterodine immediate release are dose proportional over the range of 1 to 4 mg. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_009ace02-82c5-4b40-838d-ffa14ac8343a"></a><a name="section-2.1.2"></a><p></p>
<h3>Effect of Food</h3>
<p class="First">Food intake increases the bioavailability of tolterodine (average increase 53%), but does not affect the levels of the 5-hydroxymethyl metabolite in extensive metabolizers. This change is not expected to be a safety concern and adjustment of dose is not needed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_650cea97-2060-4a58-b5b0-eb132a8a83bb"></a><a name="section-2.1.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">Tolterodine is highly bound to plasma proteins, primarily Î±<span class="Sub">1</span>-acid glycoprotein. Unbound concentrations of tolterodine average 3.7% Â± 0.13% over the concentration range achieved in clinical studies. The 5-hydroxymethyl metabolite is not extensively protein bound, with unbound fraction concentrations averaging 36% Â± 4%. The blood to serum ratio of tolterodine and the 5-hydroxymethyl metabolite averages 0.6 and 0.8, respectively, indicating that these compounds do not distribute extensively into erythrocytes. The volume of distribution of tolterodine following administration of a 1.28 mg intravenous dose is 113 Â± 26.7 L. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9cb87ae2-8dd3-443d-9266-dbd55c2973cf"></a><a name="section-2.1.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Tolterodine is extensively metabolized by the liver following oral dosing. The primary metabolic route involves the oxidation of the 5-methyl group and is mediated by the cytochrome P450 2D6 (CYP2D6) and leads to the formation of a pharmacologically active 5-hydroxymethyl metabolite. Further metabolism leads to formation of the 5-carboxylic acid and <span class="Italics">N</span>-dealkylated 5-carboxylic acid metabolites, which account for 51% Â± 14% and 29% Â± 6.3% of the metabolites recovered in the urine, respectively. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c593eb47-a903-4d0e-8de3-3b2ec21ed9c8"></a><a name="section-2.1.4.1"></a><p></p>
<h4>Variability in Metabolism</h4>
<p class="First">A subset (about 7%) of the population is devoid of CYP2D6, the enzyme responsible for the formation of the 5-hydroxymethyl metabolite of tolterodine. The identified pathway of metabolism for these individuals (â€œpoor metabolizersâ€?) is dealkylation via cytochrome P450 3A4 (CYP3A4) to <span class="Italics">N</span>-dealkylated tolterodine. The remainder of the population is referred to as â€œextensive metabolizers.â€? Pharmacokinetic studies revealed that tolterodine is metabolized at a slower rate in poor metabolizers than in extensive metabolizers; this results in significantly higher serum concentrations of tolterodine and in negligible concentrations of the 5-hydroxymethyl metabolite. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_acc07282-313f-4e6f-8d5a-f4ac0ea47142"></a><a name="section-2.1.5"></a><p></p>
<h3>Excretion</h3>
<p class="First">Following administration of a 5-mg oral dose of <span class="Sup">14</span>C-tolterodine solution to healthy volunteers, 77% of radioactivity was recovered in urine and 17% was recovered in feces in 7 days. Less than 1% (&lt; 2.5% in poor metabolizers) of the dose was recovered as intact tolterodine, and 5% to 14% (&lt; 1% in poor metabolizers) was recovered as the active 5-hydroxymethyl metabolite. </p>
<p> A summary of mean (Â± standard deviation) pharmacokinetic parameters of tolterodine immediate release and the 5-hydroxymethyl metabolite in extensive (EM) and poor (PM) metabolizers is provided in Table 1. These data were obtained following single and multiple doses of tolterodine 4 mg administered twice daily to 16 healthy male volunteers (8 EM, 8 PM). </p>
<a name="id_25887a25-0969-4595-b218-2407931c418b"></a><table width="932.000">
<caption><span>Table 1: Summary of Mean (Â± SD) Pharmacokinetic Parameters of Tolterodine and its Active Metabolite (5-Hydroxymethyl Metabolite) in Healthy Volunteers </span></caption>
<col width="11.3%">
<col width="9.1%">
<col width="10.1%">
<col width="9.1%">
<col width="10.1%">
<col width="9.1%">
<col width="10.1%">
<col width="10.1%">
<col width="10.1%">
<col width="10.9%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="10" valign="top"><p class="First">C<span class="Sub">max</span> = Maximum plasma concentration; t<span class="Sub">max</span> = Time of occurrence of C<span class="Sub">max</span>;<br>C<span class="Sub">avg</span> = Average plasma concentration; t<span class="Sub">1/2 </span>= Terminal elimination half-life; CL/F = Apparent oral clearance.<br>EM = Extensive metabolizers; PM = Poor metabolizers.</p></td></tr>
<tr><td colspan="10" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Parameter was dose-normalized from 4 mg to 2 mg.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>not applicable.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top"><span class="Bold">Tolterodine</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">5-Hydroxymethyl Metabolite</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Phenotype</span></p>
<span class="Bold">(CYP2D6)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">t<span class="Sub">max</span></span></p>
<span class="Bold">(h)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">C<span class="Sub">max</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
<span class="Bold">(mcg/L)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">C<span class="Sub">avg</span></span><a href="#footnote-1" class="Sup">*</a></p>
<span class="Bold">(mcg/L)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">t<span class="Sub">1/2</span></span></p>
<span class="Bold">(h)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">CL/F</span></p>
<span class="Bold">(L/h)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">t<span class="Sub">max</span></span></p>
<span class="Bold">(h)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">C<span class="Sub">max</span></span><a href="#footnote-1" class="Sup">*</a></p>
<span class="Bold">(mcg/L)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">C<span class="Sub">avg</span></span><a href="#footnote-1" class="Sup">*</a></p>
<span class="Bold">(mcg/L)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">t<span class="Sub">1/2</span></span></p>
<span class="Bold">(h)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Single-dose</p>
<p><span class="Bold">EM</span></p>
<span class="Bold">PM</span>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">1.6 Â± 1.5</p>1.4 Â± 0.5</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">1.6 Â± 1.2</p>10 Â± 4.9</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">0.50 Â± 0.35</p>8.3 Â± 4.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">2 Â± 0.7</p>6.5 Â± 1.6</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">534 Â± 697</p>17 Â± 7.3</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">1.8 Â± 1.4</p>Â <a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">1.8 Â± 0.7</p>
<a href="#footnote-2" class="Sup">â€ </a>Â </td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">0.62 Â± 0.26</p>
<a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">3.1 Â± 0.7</p>
<a href="#footnote-2" class="Sup">â€ </a>Â </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Multiple-dose</p>
<p><span class="Bold">EM</span></p>
<span class="Bold">PM</span>
</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">1.5 Â± 0.5</p>1.9 Â± 1</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">2.6 Â± 2.8</p>19 Â± 7.5</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">0.58 Â± 0.54</p>12 Â± 5.1</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">2.2 Â± 0.4</p>9.6 Â± 1.5</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">415 Â± 377</p>11 Â± 4.2</td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">1.2 Â± 0.5</p>
<a href="#footnote-2" class="Sup">â€ </a>Â </td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">2.4 Â±1.3</p>
<a href="#footnote-2" class="Sup">â€ </a>Â </td>
<td class="Rrule" align="center" valign="bottom">
<p class="First">0.92 Â± 0.46</p>
<a href="#footnote-2" class="Sup">â€ </a>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">2.9 Â± 0.4</p>
<a href="#footnote-2" class="Sup">â€ </a>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_59d755b3-6e04-455e-8d28-92575c1fe7c1"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics in Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6f2d2e7-1812-49c8-9b70-4766f2cfa981"></a><a name="section-2.2.1"></a><p></p>
<h3>Age</h3>
<p class="First">In Phase 1, multiple-dose studies in which tolterodine immediate-release 4 mg (2 mg bid) was administered, serum concentrations of tolterodine and of the 5-hydroxymethyl metabolite were similar in healthy elderly volunteers (aged 64 through 80 years) and healthy young volunteers (aged less than 40 years). In another Phase 1 study, elderly volunteers (aged 71 through 81 years) were given tolterodine immediate-release 2 mg or 4 mg (1 mg or 2 mg bid). Mean serum concentrations of tolterodine and the 5-hydroxymethyl metabolite in these elderly volunteers were approximately 20% and 50% higher, respectively, than reported in young healthy volunteers. However, no overall differences were observed in safety between older and younger patients on tolterodine in Phase 3, 12-week, controlled clinical studies; therefore, no tolterodine dosage adjustment for elderly patients is recommended (see <a href="#i4i_geriatric_use_id_1c25f45d-9367-427c-be09-852df85c157e">PRECAUTIONS: Geriatric Use</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c180b3db-ef1e-4540-a099-ab492a5b8cb6"></a><a name="section-2.2.2"></a><p></p>
<h3>Pediatric</h3>
<p class="First">The pharmacokinetics of tolterodine have not been established in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2040ccfa-6400-4342-9105-6f8fd222aab4"></a><a name="section-2.2.3"></a><p></p>
<h3>Gender</h3>
<p class="First">The pharmacokinetics of tolterodine immediate-release and the 5-hydroxymethyl metabolite are not influenced by gender. Mean C<span class="Sub">max</span> of tolterodine (1.6 mcg/L in males versus 2.2 mcg/L in females) and the active 5-hydroxymethyl metabolite (2.2 mcg/L in males versus 2.5 mcg/L in females) are similar in males and females who were administered tolterodine immediate-release 2 mg. Mean AUC values of tolterodine (6.7 mcgÂ·h/L in males versus 7.8 mcgÂ·h/L in females) and the 5-hydroxymethyl metabolite (10 mcgÂ·h/L in males versus 11 mcgÂ·h/L in females) are also similar. The elimination half-life of tolterodine for both males and females is 2.4 hours, and the half-life of the 5-hydroxymethyl metabolite is 3 hours in females and 3.3 hours in males. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_812b06a7-bb9a-4d3d-8f90-c479bbf8ff76"></a><a name="section-2.2.4"></a><p></p>
<h3>Race</h3>
<p class="First">Pharmacokinetic differences due to race have not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4109038-ac46-4429-a357-f0ff674f5471"></a><a name="section-2.2.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> can significantly alter the disposition of tolterodine immediate-release and its metabolites. In a study conducted in patients with creatinine clearance between 10 and 30 mL/min, tolterodine immediate-release and the 5-hydroxymethyl metabolite levels were approximately 2 to 3 fold higher in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> than in healthy volunteers. Exposure levels of other metabolites of tolterodine (e.g., tolterodine acid, <span class="Italics">N</span>-dealkylated tolterodine acid, <span class="Italics">N</span>-dealkylated tolterodine, and <span class="Italics">N</span>-dealkylated hydroxylated tolterodine) were significantly higher (10 to 30 fold) in renally impaired patients as compared to the healthy volunteers. The recommended dosage for patients with significantly reduced renal function is tolterodine tartrate tablets 1 mg twice daily (see <a href="#i4i_precautions_general_id_62d6cd16-503c-4777-9441-c63f3e4218c1">PRECAUTIONS: General</a> and <a href="#i4i_dosage_admin_id_5fc7f9e3-95d7-44b4-8aae-b27488b21ddc">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3fe0a2b4-983d-47cc-90f6-add7fb8d623c"></a><a name="section-2.2.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">Liver impairment can significantly alter the disposition of tolterodine immediate-release. In a study conducted in cirrhotic patients, the elimination half-life of tolterodine immediate-release was longer in cirrhotic patients (mean, 7.8 hours) than in healthy, young, and elderly volunteers (mean, 2 to 4 hours). The clearance of orally administered tolterodine was substantially lower in cirrhotic patients (1 Â± 1.7 L/h/kg) than in the healthy volunteers (5.7 Â± 3.8 L/h/kg). The recommended dose for patients with significantly reduced hepatic function is tolterodine tartrate tablets 1 mg twice daily (see <a href="#i4i_precautions_general_id_62d6cd16-503c-4777-9441-c63f3e4218c1">PRECAUTIONS: General</a> and <a href="#i4i_dosage_admin_id_5fc7f9e3-95d7-44b4-8aae-b27488b21ddc">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e530a242-a84b-4823-986c-7612c9700160"></a><a name="section-2.3"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_769f96c0-4583-4f5c-95cc-c6b3ebbdaaf8"></a><a name="section-2.3.1"></a><p></p>
<h3>Fluoxetine</h3>
<p class="First">Fluoxetine is a selective serotonin reuptake inhibitor and a potent inhibitor of CYP2D6 activity. In a study to assess the effect of fluoxetine on the pharmacokinetics of tolterodine immediate-release and its metabolites, it was observed that fluoxetine significantly inhibited the metabolism of tolterodine immediate-release in extensive metabolizers, resulting in a 4.8-fold increase in tolterodine AUC. There was a 52% decrease in C<span class="Sub">max</span> and a 20% decrease in AUC of the 5-hydroxymethyl metabolite. Fluoxetine thus alters the pharmacokinetics in patients who would otherwise be extensive metabolizers of tolterodine immediate release to resemble the pharmacokinetic profile in poor metabolizers. The sums of unbound serum concentrations of tolterodine immediate release and the 5-hydroxymethyl metabolite are only 25% higher during the interaction. No dose adjustment is required when DETROL and fluoxetine are coadministered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba36ef8d-c9ef-4183-819a-bf868144ad81"></a><a name="section-2.3.2"></a><p></p>
<h3>Other Drugs Metabolized by Cytochrome P450 Isoenzymes</h3>
<p class="First">Tolterodine immediate-release does not cause clinically significant interactions with other drugs metabolized by the major drug metabolizing CYP enzymes. <span class="Italics">In vivo </span>drug-interaction data show that tolterodine immediate-release does not result in clinically relevant inhibition of CYP1A2, 2D6, 2C9, 2C19, or 3A4 as evidenced by lack of influence on the marker drugs caffeine, debrisoquine, S-warfarin, and omeprazole. <span class="Italics">In vitro </span>data show that tolterodine immediate-release is a competitive inhibitor of CYP2D6 at high concentrations (Ki 1.05 Î¼M), while tolterodine immediate-release as well as the 5-hydroxymethyl metabolite are devoid of any significant inhibitory potential regarding the other isoenzymes. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8dae479e-dd44-4698-9463-7c1de038e211"></a><a name="section-2.3.3"></a><p></p>
<h3>CYP3A4 Inhibitors</h3>
<p class="First">The effect of 200 mg daily dose of ketoconazole on the pharmacokinetics of tolterodine immediate-release was studied in eight healthy volunteers, all of whom were poor metabolizers (see <a href="#i4i_section_id_c593eb47-a903-4d0e-8de3-3b2ec21ed9c8">Pharmacokinetics: Variability in Metabolism</a> for discussion of poor metabolizers). In the presence of ketoconazole, the mean C<span class="Sub">max</span> and AUC of tolterodine increased by 2 and 2.5 fold, respectively. Based on these findings, other potent CYP3A inhibitors such as other azole antifungals (e.g., itraconazole, miconazole) or macrolide antibiotics (e.g., erythromycin, clarithromycin) or cyclosporine or vinblastine may also lead to increases of tolterodine plasma concentrations (see <a href="#i4i_precautions_id_1281131e-9a0f-4901-88cb-1093451206cb">PRECAUTIONS</a>Â and <a href="#i4i_dosage_admin_id_5fc7f9e3-95d7-44b4-8aae-b27488b21ddc">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e164617e-18f3-43ba-bb44-cc369bbe97cd"></a><a name="section-2.3.4"></a><p></p>
<h3>Warfarin</h3>
<p class="First">In healthy volunteers, coadministration of tolterodine immediate-release 4 mg (2 mg bid) for 7 days and a single dose of warfarin 25 mg on day 4 had no effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, Factor VII suppression, or on the pharmacokinetics of warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_491040df-dd3e-4c35-b345-2237023170f8"></a><a name="section-2.3.5"></a><p></p>
<h3>Oral Contraceptives</h3>
<p class="First">Tolterodine immediate-release 4 mg (2 mg bid) had no effect on the pharmacokinetics of an oral contraceptive (ethinyl estradiol 30 mcg/levonorgestrel 150 mcg) as evidenced by the monitoring of ethinyl estradiol and levonorgestrel over a 2-month cycle in healthy female volunteers. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01e212b0-53ed-4f0a-a6b2-eeccf5e88e02"></a><a name="section-2.3.6"></a><p></p>
<h3>Diuretics</h3>
<p class="First">Coadministration of tolterodine immediate-release up to 8 mg (4 mg bid) for up to 12 weeks with diuretic agents, such as indapamide, hydrochlorothiazide, triamterene, bendroflumethiazide, chlorothiazide, methylchlorothiazide, or furosemide, did not cause any adverse electrocardiographic (ECG) effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56c2b88d-d7e4-4496-a6b9-9409e9a3608e"></a><a name="section-2.4"></a><p></p>
<h2>Cardiac Electrophysiology</h2>
<p class="First">The effect of 2 mg BID and 4 mg BID of tolterodine immediate-release (IR) on the QT interval was evaluated in a 4-way crossover, double-blind, placebo- and active-controlled (moxifloxacin 400 mg QD) study in healthy male (N = 25) and female (N = 23) volunteers aged 18 to 55 years. Study subjects [approximately equal representation of CYP2D6 extensive metabolizers (EMs) and poor metabolizers (PMs)] completed sequential 4-day periods of dosing with moxifloxacin 400 mg QD, tolterodine 2 mg BID, tolterodine 4 mg BID, and placebo. The 4 mg BID dose of tolterodine IR (2 times the highest recommended dose) was chosen because this dose results in tolterodine exposure similar to that observed upon coadministration of tolterodine 2 mg BID with potent CYP3A4 inhibitors in patients who are CYP2D6 poor metabolizers (see <a href="#i4i_interactions_id_a8f0a192-5004-40d5-9813-2be9eaa54009">PRECAUTIONS: Drug Interactions</a>). QT interval was measured over a 12-hour period following dosing, including the time of peak plasma concentration (T<span class="Sub">max</span>) of tolterodine and at steady-state (Day 4 of dosing). </p>
<p> Table 2 summarizes the mean change from baseline to steady state in corrected QT interval (QTc) relative to placebo at the time of peak tolterodine (one hour) and moxifloxacin (2 hour) concentrations. Both Fridericiaâ€™s (QTcF) and a population-specific (QTcP) method were used to correct QT interval for heart rate. No single QT correction method is known to be more valid than others. QT interval was measured manually and by machine, and data from both are presented. The mean increase of heart rate associated with a 4 mg/day dose of tolterodine in this study was 2 beats/minute and 6.3 beats/minute with 8 mg/day tolterodine. The change in heart rate with moxifloxacin was 0.5 beats/minute. </p>
<a name="id_8c91ec25-8c9b-49ab-ac9e-51e3e19363cf"></a><table width="872.000">
<caption><span>Table 2: Mean (CI) Change in QTc from Baseline to Steady-State (Day 4 of Dosing) at T<span class="Sub">max</span> (Relative to Placebo)</span></caption>
<col width="17.9%">
<col width="16.6%">
<col width="15.6%">
<col width="16.6%">
<col width="16.6%">
<col width="16.6%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>At T<span class="Sub">max </span>of one hr; 95% Confidence Interval</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€ </a></dt>
<dd>At T<span class="Sub">max</span> of 2 hr; 90% Confidence Interval</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€¡</a></dt>
<dd>The effect on QT interval with 4 days of moxifloxacin dosing in this QT trial may be greater than typically observed in QT trials of other drugs. </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Drug/Dose</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">N</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">QTcF</span></p>
<p><span class="Bold">(msec)</span></p>
<span class="Bold">(manual)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">QTcF</span></p>
<p><span class="Bold">(msec)</span></p>
<span class="Bold">(machine)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">QTcP</span></p>
<p><span class="Bold">(msec)</span></p>
<span class="Bold">(manual)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">QTcP</span></p>
<p><span class="Bold">(msec)</span></p>
<span class="Bold">(machine)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Tolterodine </p>2 mg BID<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">48</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">5.01</p>(0.28, 9.74)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">1.16</p>(-2.99, 5.30)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">4.45</p>(-0.37, 9.26)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">2</p>(-1.81, 5.81)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Tolterodine</p>4 mg BID<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">48</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">11.84</p>(7.11, 16.58)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">5.63</p>(1.48, 9.77)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">10.31</p>(5.49, 15.12)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">8.34</p>(4.53, 12.15)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Moxifloxacin</p>400 mg QD<a name="footnote-reference-4" href="#footnote-4" class="Sup">â€ </a>
</td>
<td class="Rrule" align="center" valign="top">45</td>
<td class="Rrule" align="center" valign="top">
<p class="First">19.26<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€¡</a></p>(15.49, 23.03)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">8.90</p>(4.77, 13.03)</td>
<td class="Rrule" align="center" valign="top">
<p class="First">19.10<a href="#footnote-5" class="Sup">â€¡</a></p>(15.32, 22.89)</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">9.29</p>(5.34, 13.24)</td>
</tr>
</tbody>
</table>
<p> The reason for the difference between machine and manual read of QT interval is unclear. </p>
<p> The QT effect of tolterodine immediate-release tablets appeared greater for 8 mg/day (2 times the therapeutic dose) compared to 4 mg/day. The effect of tolterodine 8 mg/day was not as large as that observed after 4 days of therapeutic dosing with the active control moxifloxacin. However, the confidence intervals overlapped. </p>
<p> Tolterodineâ€™s effect on QT interval was found to correlate with plasma concentration of tolterodine. There appeared to be a greater QTc interval increase in CYP2D6 poor metabolizers than in CYP2D6 extensive metabolizers after tolterodine treatment in this study. </p>
<p> This study was not designed to make direct statistical comparisons between drugs or dose levels. There has been no association of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> in the international post-marketing experience with tolterodine tartrate tablets or tolterodine tartrate extended-release capsules (see <a href="#i4i_section_id_024fd245-38b9-4db9-802d-19cf0bada035">PRECAUTIONS: Patients with Congenital or Acquired QT Prolongation</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_72917972-07e4-4886-b628-bdf48d093fc7"></a><a name="section-3"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">Tolterodine tartrate tablets were evaluated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and frequency in four randomized, double-blind, placebo-controlled, 12-week studies. A total of 853 patients received tolterodine tartrate tablets 2 mg twice daily and 685 patients received placebo. The majority of patients were Caucasian (95%) and female (78%), with a mean age of 60 years (range, 19 to 93 years). At study entry, nearly all patients perceived they had urgency and most patients had increased <span class="product-label-link" type="condition" conceptid="200843" conceptname="Finding of frequency of urination">frequency of micturitions</span> and <span class="product-label-link" type="condition" conceptid="193326" conceptname="Urge incontinence of urine">urge incontinence</span>. These characteristics were well balanced across treatment groups for the studies. </p>
<p> The efficacy endpoints for study 007 (see <a href="#id_c85cded7-9d77-4f04-8f77-d5d88dcf0fd5">Table 3</a>) included the change from baseline for: </p>
<ul>
<li>Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes per week </li>
<li>Number of micturitions per 24 hours (averaged over 7 days) </li>
<li>Volume of urine voided per micturition (averaged over 2 days) </li>
</ul>
<p> The efficacy endpoints for studies 008, 009, and 010 (see <a href="#id_e3d6dc04-d377-4d1a-84f3-492c2e8da621">Table 4</a>) were identical to the above endpoints with the exception that the number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes was per 24 hours (averaged over 7 days). </p>
<a name="id_c85cded7-9d77-4f04-8f77-d5d88dcf0fd5"></a><table width="941.000">
<caption><span>Table 3: 95% Confidence Intervals (CI) for the Difference Between Tolterodine Tartrate Tablets (2 mg bid) and Placebo for the Mean Change at Week 12 from Baseline in Study 007</span></caption>
<col width="32.1%">
<col width="22.6%">
<col width="22.6%">
<col width="22.6%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">SD = Standard Deviation.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>The difference between tolterodine tartrate tablets and placebo was statistically significant.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Tolterodine Tartrate Tablets</span></p>
<p><span class="Bold">(SD)</span></p>
<span class="Bold">N = 514</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(SD)</span></p>
<span class="Bold">N = 508</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Difference</span></p>
<span class="Bold">(95% CI)</span>
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes per Week</p>
<p>Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Mean change from baseline</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">23.2</p>-10.6 (17)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">23.3</p>-6.9 (15)</td>
<td class="Botrule" align="center" valign="bottom">-3.7 (-5.7, -1.6)</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">Number of Micturitions per 24 Hours</p>
<p>Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Mean change from baseline</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">11.1</p>-1.7 (3.3)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">11.3</p>-1.2 (2.9)</td>
<td class="Botrule" align="center" valign="bottom">-0.5<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> (-0.9, -0.1)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<p class="First">Volume Voided per Micturition (mL)</p>
<p>Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Mean change from baseline</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">137</p>29 (47)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">136</p>14 (41)</td>
<td class="Botrule" align="center" valign="bottom">15<a href="#footnote-6" class="Sup">*</a> (9, 21)</td>
</tr>
</tbody>
</table>
<a name="id_e3d6dc04-d377-4d1a-84f3-492c2e8da621"></a><table width="941.000">
<caption><span>Table 4: 95% Confidence Intervals (CI) for the Difference Between Tolterodine Tartrate Tablets (2 mg bid) and Placebo for the Mean Change at Week 12 from Baseline in Studies 008, 009, 010</span></caption>
<col width="32.1%">
<col width="22.6%">
<col width="22.6%">
<col width="22.6%">
<tfoot>
<tr class="Last"><td class="Botrule Lrule" align="left" colspan="4" valign="top">SD = Standard deviation.</td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>The difference between tolterodine tartrate tablets and placebo was statistically significant.</dd>
</dl></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"><span class="Bold">Study</span></td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Tolterodine Tartrate Tablets</span></p>
<span class="Bold">(SD)</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Placebo</span></p>
<span class="Bold">(SD)</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">Difference</span></p>
<span class="Bold">(95% CI)</span>
</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top"><span class="Bold">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes per 24 Hours</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First">008Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">93</p>
<p>2.9</p>-1.3 (3.2)</td>
<td align="center" valign="bottom">
<p class="First">40</p>
<p>3.3</p>-0.9 (1.5)</td>
<td align="center" valign="bottom"><p class="First">0.5 (-1.3, 0.3)</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">009Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">116</p>
<p>3.6</p>-1.7 (2.5)</td>
<td align="center" valign="bottom">
<p class="First">55</p>
<p>3.5</p>-1.3 (2.5)</td>
<td align="center" valign="bottom"><p class="First">-0.4 (-1, 0.2)</p></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">010Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">90</p>
<p>3.7</p>-1.6 (2.4)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">50</p>
<p>3.5</p>-1.1 (2.1)</td>
<td class="Botrule" align="center" valign="bottom">-0.5 (-1.1, 0.1)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top"><span class="Bold">Number of Micturitions per 24 Hours</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First">008Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">118</p>
<p>11.5</p>-2.7 (3.8)</td>
<td align="center" valign="bottom">
<p class="First">56</p>
<p>11.7</p>-1.6 (3.6)</td>
<td align="center" valign="bottom"><p class="First">-1.2<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> (-2, -0.4)</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">009Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">128</p>
<p>11.2</p>-2.3 (2.1)</td>
<td align="center" valign="bottom">
<p class="First">64</p>
<p>11.3</p>-1.4 (2.8)</td>
<td align="center" valign="bottom"><p class="First">-0.9<a href="#footnote-7" class="Sup">*</a> (-1.5, -0.3)</p></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">
<p class="First">010Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">108</p>
<p>11.6</p>-1.7 (2.3)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">56</p>
<p>11.6</p>-1.4 (2.8)</td>
<td class="Botrule" align="center" valign="bottom">-0.38 (-1.1, 0.3)</td>
</tr>
<tr><td class="Botrule" align="left" colspan="4" valign="top"><span class="Bold">Volume Voided per Micturition (mL)</span></td></tr>
<tr>
<td align="left" valign="top">
<p class="First">008Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">118</p>
<p>166</p>38 (54)</td>
<td align="center" valign="bottom">
<p class="First">56</p>
<p>157</p>6 (42)</td>
<td align="center" valign="bottom"><p class="First">32<a href="#footnote-7" class="Sup">*</a> (18, 46)</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">009Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>Â Â Â Â Â Â Â Â Â Mean change from baseline</td>
<td align="center" valign="bottom">
<p class="First">129</p>
<p>155</p>36 (50)</td>
<td align="center" valign="bottom">
<p class="First">64</p>
<p>158</p>10 (47)</td>
<td align="center" valign="bottom"><p class="First">26<a href="#footnote-7" class="Sup">*</a> (14, 38)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">
<p class="First">010Â Â Â Number of patients</p>
<p>Â Â Â Â Â Â Â Â Â Mean baseline</p>
<p>Â Â Â Â Â Â Â Â Â Mean change from baseline</p>
</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">108</p>
<p>155</p>31 (45)</td>
<td class="Botrule" align="center" valign="bottom">
<p class="First">56</p>
<p>160</p>13 (52)</td>
<td class="Botrule" align="center" valign="bottom">18<a href="#footnote-7" class="Sup">*</a> (4, 32)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_db1f47aa-3e59-4bdd-9a55-2e7e995058ed"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Tolterodine tartrate tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and frequency.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_37e46bb7-05e2-4d74-801a-713befda7184"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Tolterodine tartrate tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, gastric retention, or uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Tolterodine tartrate tablets are also contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate tablets, are metabolized to 5-hydroxymethyyl tolterodine. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_fdd55ad9-da88-4196-a5d6-c02c1a394adc"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of tolterodine tartrate tablets. In the event of difficulty in breathing, upper airway obstruction, or <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, tolterodine tartrate tablets should be discontinued and appropriate therapy promptly provided.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1281131e-9a0f-4901-88cb-1093451206cb"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_62d6cd16-503c-4777-9441-c63f3e4218c1"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac635175-45ca-4ec4-ba90-054d329e0118"></a><a name="section-7.1.1"></a><p></p>
<h3>Risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> and Gastric Retention</h3>
<p class="First">Tolterodine tartrate tablets should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> and to patients with gastrointestinal obstructive disorders, such as <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>, because of the risk of gastric retention (see <a href="#i4i_contraindications_id_37e46bb7-05e2-4d74-801a-713befda7184">CONTRAINDICATIONS</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_096338b1-e96b-460b-9fbf-3c1ea14c69d9"></a><a name="section-7.1.2"></a><p></p>
<h3>Decreased Gastrointestinal Motility</h3>
<p class="First">Tolterodine tartrate tablets, like other antimuscarinic drugs, should be used with caution in patients with decreased gastrointestinal motility. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0650179f-cfdf-4b78-abd2-b83918b8f07c"></a><a name="section-7.1.3"></a><p></p>
<h3>Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h3>
<p class="First">Tolterodine tartrate tablets should be used with caution in patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc3bc200-be74-447b-a435-6fa574344b6e"></a><a name="section-7.1.4"></a><p></p>
<h3>Central Nervous System (CNS) Effects</h3>
<p class="First">Tolterodine tartrate tablets are associated with anticholinergic central nervous system (CNS) effects including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (see <a href="#i4i_adverse_effects_id_ed54049e-8586-46be-8dc7-1e044acc2842">ADVERSE REACTIONS</a>). Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until the drugâ€™s effects have been determined. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d137e93-75fc-4915-9460-8adebb98d6d1"></a><a name="section-7.1.5"></a><p></p>
<h3>Reduced Hepatic and Renal Function</h3>
<p class="First">For patients with significantly reduced hepatic function or renal function, the recommended dose of tolterodine tartrate tablets is 1 mg twice daily (see <a href="#i4i_section_id_59d755b3-6e04-455e-8d28-92575c1fe7c1">CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations</a>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_094466a5-b498-4e6b-8e72-4a8ba631ca4d"></a><a name="section-7.1.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia Gravis</span></h3>
<p class="First">Tolterodine tartrate tablets should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, a disease characterized by decreased cholinergic activity at the neuromuscular junction. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_024fd245-38b9-4db9-802d-19cf0bada035"></a><a name="section-7.2"></a><p></p>
<h2>Patients with Congenital or Acquired QT Prolongation</h2>
<p class="First">In a study of the effect of tolterodine immediate-release tablets on the QT interval (See <a href="#i4i_section_id_56c2b88d-d7e4-4496-a6b9-9409e9a3608e">CLINICAL PHARMACOLOGY: Cardiac Electrophysiology</a>), the effect on the QT interval appeared greater for 8 mg/day (2 times the therapeutic dose) compared to 4 mg/day and was more pronounced in CYP2D6 poor metabolizers (PM) than extensive metabolizers (EMs). The effect of tolterodine 8 mg/day was not as large as that observed after 4 days of therapeutic dosing with the active control moxifloxacin. However, the confidence intervals overlapped. These observations should be considered in clinical decisions to prescribe tolterodine tartrate tablets for patients with a known history of QT prolongation or patients who are taking Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications (see <a href="#i4i_interactions_id_a8f0a192-5004-40d5-9813-2be9eaa54009">PRECAUTIONS: Drug Interactions</a>). There has been no association of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span> in the international post-marketing experience with tolterodine tartrate tablets or tolterodine tartrate extended-release capsules. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_42a6e59b-bef9-488d-b038-5beb9c8a2644"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be informed that antimuscarinic agents such as tolterodine tartrate tablets may produce the following effects: <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects have been determined. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a8f0a192-5004-40d5-9813-2be9eaa54009"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0122ca52-3eec-4d5c-95f4-12fb49565628"></a><a name="section-7.4.1"></a><p></p>
<h3>CYP3A4 Inhibitors</h3>
<p class="First">Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see <a href="#i4i_section_id_c593eb47-a903-4d0e-8de3-3b2ec21ed9c8">CLINICAL PHARMACOLOGY: Variability in Metabolism</a> and <a href="#i4i_interactions_id_e530a242-a84b-4823-986c-7612c9700160">Drug-Drug Interactions</a>). For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (e.g., itraconazole, miconazole) or macrolide antibiotics (e.g., erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of tolterodine tartrate tablets is 1 mg twice daily (see <a href="#i4i_dosage_admin_id_5fc7f9e3-95d7-44b4-8aae-b27488b21ddc">DOSAGE AND ADMINISTRATION</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_17d1b23f-e9bd-4df0-ad7e-ceef9c012bde"></a><a name="section-7.5"></a><p></p>
<h2>Drug-Laboratory-Test Interactions</h2>
<p class="First">Interactions between tolterodine and laboratory tests have not been studied. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_8e8620f9-690d-49a7-8ea8-f878c62a6770"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with tolterodine were conducted in mice and rats. At the maximum tolerated dose in mice (30 mg/kg/day), female rats (20 mg/kg/day), and male rats (30 mg/kg/day), AUC values obtained for tolterodine were 355, 291, and 462 mcgÂ·h/L, respectively. In comparison, the human AUC value for a 2 mg dose administered twice daily is estimated at 34 mcgÂ·h/L. Thus, tolterodine exposure in the carcinogenicity studies was 9- to 14-fold higher than expected in humans. No increase in tumors was found in either mice or rats. </p>
<p> No mutagenic effects of tolterodine were detected in a battery of <span class="Italics">in vitro </span>tests, including bacterial mutation assays (Ames test) in four <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>and in two <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Escherichia coli, </span>a gene mutation assay in L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, and chromosomal aberration tests in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Tolterodine was also negative <span class="Italics">in vivo </span>in the bone marrow micronucleus test in the mouse. </p>
<p> In female mice treated for 2 weeks before mating and during gestation with 20 mg/kg/day (corresponding to AUC value of about 500 mcgÂ·h/L), neither effects on reproductive performance or fertility were seen. Based on AUC values, the systemic exposure was about 15-fold higher in animals than in humans. In male mice, a dose of 30 mg/kg/day did not induce any adverse effects on fertility. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_014ca4f4-95e5-41d0-83bd-883e113229a3"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_9242ba6e-7a2e-46a0-a129-6b68d6c477c9"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category C</h3>
<p class="First">At oral doses of 20 mg/kg/day (approximately 14 times the human exposure), no anomalies or malformations were observed in mice. When given at doses of 30 to 40 mg/kg/day, tolterodine has been shown to be embryolethal, reduce fetal weight, and increase the incidence of fetal abnormalities (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, digital abnormalities, intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and various skeletal abnormalities, primarily reduced ossification) in mice. At these doses, the AUC values were about 20- to 25-fold higher than in humans. Rabbits treated subcutaneously at a dose of 0.8 mg/kg/day achieved an AUC of 100 mcgÂ·h/L, which is about 3-fold higher than that resulting from the human dose. This dose did not result in any embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. There are no studies of tolterodine in pregnant women. Therefore, tolterodine tartrate tablets should be used during pregnancy only if the potential benefit for the mother justifies the potential risk to the fetus. </p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_96bee03a-486d-484e-a961-627b79b376be"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Tolterodine is excreted into the milk in mice. Offspring of female mice treated with tolterodine 20 mg/kg/day during the lactation period had slightly reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. The offspring regained the weight during the maturation phase. It is not known whether tolterodine is excreted in human milk; therefore, tolterodine tartrate tablets should not be administered during nursing. A decision should be made whether to discontinue nursing or to discontinue tolterodine tartrate tablets in nursing mothers. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1b2318ed-9397-4be5-ae43-009811654dac"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Efficacy in the pediatric population has not been demonstrated. </p>
<p> Two pediatric phase 3 randomized, placebo-controlled, double-blind, 12-week studies were conducted using tolterodine tartrate extended-release capsules. A total of 710 pediatric patients (486 on tolterodine tartrate extended-release capsules and 224 on placebo) aged 5 to 10 years with <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> and urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> were studied. The percentage of patients with <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> was higher in patients treated with tolterodine tartrate extended-release capsules (6.6%) compared to patients who received placebo (4.5%). Aggressive, abnormal and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> behavior and attention disorders occurred in 2.9% of children treated with tolterodine tartrate extended-release capsules compared to 0.9% of children treated with placebo. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_1c25f45d-9367-427c-be09-852df85c157e"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the 1,120 patients who were treated in the four Phase 3, 12-week clinical studies of tolterodine tartrate tablets, 474 (42%) were 65 to 91 years of age. No overall differences in safety were observed between the older and younger patients (see <a href="#i4i_section_id_59d755b3-6e04-455e-8d28-92575c1fe7c1">CLINICAL PHARMACOLOGY: Pharmacokinetics in Special Populations</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ed54049e-8586-46be-8dc7-1e044acc2842"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The Phase 2 and 3 clinical trial program for tolterodine tartrate tablets included 3,071 patients who were treated with tolterodine tartrate tablets (N = 2,133) or placebo (N = 938). The patients were treated with 1, 2, 4, or 8 mg/day for up to 12 months. No differences in the safety profile of tolterodine were identified based on age, gender, race, or metabolism. </p>
<p> The data described below reflect exposure to tolterodine tartrate tablets 2 mg bid in 986 patients and to placebo in 683 patients exposed for 12 weeks in five Phase 3, controlled clinical studies. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and approximating rates. </p>
<p> Sixty-six percent of patients receiving tolterodine tartrate tablets 2 mg bid reported adverse events versus 56% of placebo patients. The most common adverse events reported by patients receiving tolterodine tartrate tablets were <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span> (accommodation abnormalities), <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span> are expected side effects of antimuscarinic agents. </p>
<p> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span> was the most frequently reported adverse event for patients treated with tolterodine tartrate tablets 2 mg bid in the Phase 3 clinical studies, occurring in 34.8% of patients treated with tolterodine tartrate tablets and 9.8% of placebo-treated patients. One percent of patients treated with tolterodine tartrate tablets discontinued treatment due to <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. </p>
<p> The frequency of discontinuation due to adverse events was highest during the first 4 weeks of treatment. Seven percent of patients treated with tolterodine tartrate tablets 2 mg bid discontinued treatment due to adverse events versus 6% of placebo patients. The most common adverse events leading to discontinuation of tolterodine tartrate tablets were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. </p>
<p> Three percent of patients treated with tolterodine tartrate tablets 2 mg bid reported a serious adverse event versus 4% of placebo patients. Significant ECG changes in QT and QTc have not been demonstrated in clinical-study patients treated with tolterodine tartrate tablets 2 mg bid. Table 5 lists the adverse events reported in 1% or more of the patients treated with tolterodine tartrate tablets 2 mg bid in the 12-week studies. The adverse events are reported regardless of causality. </p>
<a name="id_08024adb-26eb-4485-805c-b2abc61b4e96"></a><table width="873.000">
<caption><span>Table 5: Incidence<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> (%) of Adverse Events Exceeding Placebo Rate and Reported in &gt; 1% of Patients Treated with Tolterodine Tartrate Tablets (2 mg bid) in 12-Week, Phase 3 Clinical Studies </span></caption>
<col width="25.8%">
<col width="25.4%">
<col width="24.4%">
<col width="24.4%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>in nearest integer.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body System</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Adverse Event</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">% Tolterodine Tartrate Tablets</span></p>
<span class="Bold">N = 986</span>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First"><span class="Bold">% Placebo</span></p>
<span class="Bold">N = 683</span>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Autonomic Nervous</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">Accommodation abnormal</span></p><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">2</p>35</td>
<td class="Botrule" align="center" valign="top">
<p class="First">1</p>10</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">General</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">2</p>
<p>4</p>
<p>7</p>3</td>
<td class="Botrule" align="center" valign="top">
<p class="First">1</p>
<p>3</p>
<p>5</p>2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Central/Peripheral Nervous</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>/<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
<td class="Botrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Gastrointestinal</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">5</p>
<p>7</p>
<p>4</p>4</td>
<td class="Botrule" align="center" valign="top">
<p class="First">3</p>
<p>4</p>
<p>3</p>1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Urinary</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Skin/Appendages</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Musculoskeletal</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Vision</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">Xerophthalmia</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Psychiatric</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Metabolic/Nutritional</td>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="left" valign="top">Resistance Mechanism</td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="center" valign="top">1</td>
<td class="Botrule" align="center" valign="top">0</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f40d2719-0b57-4ce8-98c4-bc5072165e04"></a><a name="section-8.1"></a><p></p>
<h2>Post-Marketing Surveillance</h2>
<p class="First">The following events have been reported in association with tolterodine use in worldwide post-marketing experience: <span class="Bold"><span class="Italics">General: </span></span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; <span class="Bold"><span class="Italics">Cardiovascular: </span></span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>; <span class="Bold"><span class="Italics">Central/Peripheral Nervous: </span></span><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. </p>
<p> Reports of aggravation of symptoms of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>) have been reported after tolterodine therapy was initiated in patients taking <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> inhibitors for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. </p>
<p> Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of tolterodine in their causation cannot be reliably determined. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_5fc2d07d-5506-4ad7-9cdd-a2b66d6ad8cb"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A 27-month-old child who ingested 5 to 7 tolterodine tartrate tablets 2 mg was treated with a suspension of activated charcoal and was hospitalized overnight with symptoms of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. The child fully recovered. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2fcf4752-26b1-43ab-a21a-46b417baa0ff"></a><a name="section-9.1"></a><p></p>
<h2>Management of Overdosage</h2>
<p class="First">Overdosage with tolterodine tartrate tablets can potentially result in severe central anticholinergic effects and should be treated accordingly. </p>
<p> ECG monitoring is recommended in the event of overdosage. In dogs, changes in the QT interval (slight prolongation of 10% to 20%) were observed at a suprapharmacologic dose of 4.5 mg/kg, which is about 68 times higher than the recommended human dose. In clinical trials of normal volunteers and patients, QT interval prolongation was observed with tolterodine immediate release at doses up to 8 mg (4 mg bid) and higher doses were not evaluated (see <a href="#i4i_section_id_024fd245-38b9-4db9-802d-19cf0bada035">PRECAUTIONS: Patients with Congenital or Acquired QT Prolongation</a>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_5fc7f9e3-95d7-44b4-8aae-b27488b21ddc"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The initial recommended dose of tolterodine tartrate tablets is 2 mg twice daily. The dose may be lowered to 1 mg twice daily based on individual response and tolerability. For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose of tolterodine tartrate tablets is 1 mg twice daily (see <a href="#i4i_precautions_general_id_62d6cd16-503c-4777-9441-c63f3e4218c1">PRECAUTIONS: General</a>, <a href="#i4i_section_id_1d137e93-75fc-4915-9460-8adebb98d6d1">PRECAUTIONS: Reduced Hepatic and Renal Function</a>, and <a href="#i4i_interactions_id_a8f0a192-5004-40d5-9813-2be9eaa54009">PRECAUTIONS: Drug Interactions</a>). </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_170229a1-9c79-42fb-831c-294b72999f46"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Tolterodine Tartrate Tablets are available containing 1 mg or 2 mg of tolterodine tartrate. </p>
<p>The 1 mg tablets are white, film-coated, round, unscored tablets debossed with <span class="Bold">M </span>on one side of the tablet and <span class="Bold">TT1</span> on the other side. They are available as follows:</p>
<p>NDC 0378-5445-91<br>bottles of 60 tablets</p>
<p>NDC 0378-5445-69<br>bottles of 140 tablets</p>
<p>NDC 0378-5445-05<br>bottles of 500 tablets</p>
<p>The 2 mg tablets are white, film-coated, round, unscored tablets debossed with <span class="Bold">M </span>on one side of the tablet and <span class="Bold">TT2</span> on the other side. They are available as follows:</p>
<p>NDC 0378-5446-91<br>bottles of 60 tablets</p>
<p>NDC 0378-5446-69<br>bottles of 140 tablets</p>
<p>NDC 0378-5446-05<br>bottles of 500 tablets</p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Patient Information Leaflet with each prescription.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_bf3b6ae4-65aa-4b57-bab6-2351f4b569a4"></a><a name="section-12"></a><p></p>
<h1>Â </h1>
<p class="First"><span class="Bold">PATIENT INFORMATION LEAFLET<br>TOLTERODINE TARTRATE TABLETS<br>(tol terâ€² oh deen tarâ€² trate)<br>1 mg and 2 mg</span></p>
<p><span class="Bold">Read the Patient Information that comes with tolterodine tartrate tablets before you start using it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your condition or your treatment. Only your doctor can determine if treatment with tolterodine tartrate tablets is right for you. </span></p>
<p><span class="Bold">What are tolterodine tartrate tablets? </span></p>
<p>Tolterodine tartrate tablets are a prescription medicine for <span class="Bold">adults </span>used to treat the following symptoms due to a condition called <span class="Bold"><span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span></span>: </p>
<ul>
<li>Urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>: a strong need to urinate with leaking or wetting <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span> </li>
<li>Urgency: a strong need to urinate right away </li>
<li>Frequency: urinating often </li>
</ul>
<p>Tolterodine tartrate extended release capsules did not help the symptoms of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> when studied in children. </p>
<p><span class="Bold">What is <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span>? </span></p>
<p><span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">Overactive bladder</span> happens when you cannot control your bladder muscle. When the muscle contracts too often or cannot be controlled, you get symptoms of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span>, which are leakage of urine (urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>), needing to urinate right away (urgency), and needing to urinate often (frequency). </p>
<p><span class="Bold">Who should not take tolterodine tartrate tablets? </span></p>
<p>Do not take tolterodine tartrate tablets if you: </p>
<ul>
<li>are not able to empty your bladder (<span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>) </li>
<li>have delayed or slow emptying of your stomach (gastric retention) </li>
<li>have an eye problem called â€œuncontrolled narrow-angle glaucomaâ€? </li>
<li>are allergic to tolterodine tartrate tablets or to any of its ingredients. See the end of this leaflet for a complete list of ingredients</li>
<li>are allergic to Toviaz<span class="Sup">Â®</span>* which contains fesoterodine. </li>
</ul>
<p><span class="Bold">What should I tell my doctor before starting tolterodine tartrate tablets? </span></p>
<p>Before starting tolterodine tartrate tablets, tell your doctor about all of your medical and other conditions that may affect the use of tolterodine tartrate tablets, including: </p>
<ul>
<li>stomach or intestinal problems or problems with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
<li>problems emptying your bladder or if you have a weak urine stream </li>
<li>treatment for an eye problem called narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> </li>
<li>liver problems </li>
<li>kidney problems </li>
<li>a condition called <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> </li>
<li>if you or any family members have a rare heart condition called QT prolongation (<span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>) </li>
<li>if you are pregnant or trying to become pregnant. It is not known if DETROL could harm your unborn baby. </li>
<li>if you are breast-feeding. It is not known if tolterodine tartrate passes into your breast milk or if it can harm your baby. Talk to your doctor about the best way to feed your baby if you take tolterodine tartrate tablets. </li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Other medicines can affect how your body handles tolterodine tartrate tablets. Your doctor may use a lower dose of tolterodine tartrate tablets if you are taking: </p>
<ul>
<li>Certain medicines for fungus or <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infections</span> </li>
<li>Certain medicines for <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> </li>
<li>Sandimmune<span class="Sup">Â®</span>* (cyclosporine) or Velban<span class="Sup">Â®</span>* (vinblastine) </li>
</ul>
<p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure. </p>
<p>Know the medicines you take. Keep a list of them with you to show your doctor or pharmacist each time you get a new medicine. </p>
<p><span class="Bold">How should I take tolterodine tartrate tablets? </span></p>
<ul>
<li>Take tolterodine tartrate tablets exactly as your doctor tells you to take it. </li>
<li>Your doctor will tell you how many tolterodine tartrate tablets to take and when to take them.</li>
<li>Do not change your dose unless told to do so by your doctor. </li>
<li>You can take tolterodine tartrate tablets with or without food. </li>
<li>Take tolterodine tartrate tablets at the same times each day. </li>
<li>If you miss a dose of tolterodine tartrate tablets, just take your next regular dose at your next regular time. Do not try to make up for your missed dose. </li>
<li>If you take too much tolterodine tartrate tablets, call your doctor, or go to the hospital emergency room right away. </li>
</ul>
<p><span class="Bold">What should I avoid while taking tolterodine tartrate tablets?</span></p>
<p>Medicines like tolterodine tartrate tablets can cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Do not drive, operate machinery, or do other dangerous activities until you know how tolterodine tartrate tablets affect you.  </p>
<p><span class="Bold">What are possible side effects of tolterodine tartrate tablets?</span></p>
<p>Tolterodine tartrate tablets may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be serious. Symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, throat or tongue. If you experience these symptoms, you should stop taking tolterodine tartrate tablets and get emergency medical help right away.Â  </p>
<p>The most common side effects with tolterodine tartrate tablets are: </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> </li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </li>
</ul>
<p>Tell your doctor if you have any side effects that bother you or that do not go away. </p>
<p>These are not all the side effects with tolterodine tartrate tablets. For a complete list, ask your doctor or pharmacist. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. </span></p>
<p><span class="Bold">How do I store tolterodine tartrate tablets? </span></p>
<ul>
<li>Store tolterodine tartrate tablets at 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]</li>
<li>Keep it in a dry place. </li>
</ul>
<p><span class="Bold">Keep tolterodine tartrate tablets and all medicines out of the reach of children. </span></p>
<p><span class="Bold">General information about tolterodine tartrate tablets</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in the patient information leaflet. Only use tolterodine tartrate tablets the way your doctor tells you. Do not give tolterodine tartrate tablets to other people even if they have the same symptoms you have. It may harm them. </p>
<p>This leaflet summarizes the most important information about tolterodine tartrate tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about tolterodine tartrate tablets that is written for health professionals. You can also call 1-877-446-3679 (1-877-4-INFO-RX). </p>
<p><span class="Bold">What are the ingredients in tolterodine tartrate tablets? </span></p>
<p><span class="Bold">Active ingredients: </span>tolterodine tartrate </p>
<p><span class="Bold">Inactive ingredients: </span>colloidal silicon dioxide, dibasic calcium phosphate, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium starch glycolate and titanium dioxide.</p>
<p>*The following are registered trademarks of their respective manufacturers: SANDIMMUNE<span class="Sup">Â®</span>/Novartis, VELBAN<span class="Sup">Â®</span>/Lilly and TOVIAZ<span class="Sup">Â®</span>/Pfizer.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV 26505 U.S.A.</p>
<p>REVISED AUGUST 2012<br>TOLT:R2ppt</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_d80b7c50-40dc-4408-9a6d-4a66f617e83a"></a><a name="section-13"></a><p></p>
<h1>Â Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mg</span></p>
<p><span class="Bold">NDC 0378-5445-91</span></p>
<p><span class="Bold">Tolterodine<br>Tartrate<br>Tablets<br>1 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying<br>Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Rx only 60 Tablets</span></p>
<p>Each film-coated tablet contains:<br>Tolterodine tartrate 1 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication<br>out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).<br>[See USP Controlled Room<br>Temperature.]</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM5445D</span></p>
<div class="Figure"><img alt="Tolterodine Tartrate Tablets 1 mg Bottle Labels " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=304023e8-57ad-4dd7-9cf0-a4524623aa6c&amp;name=bfc370b4-6a62-44de-a353-dd59768e3133-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_860efa65-9ff0-409c-840a-7df98f0e0b95"></a><a name="section-14"></a><p></p>
<h1>Â Â Â Â </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 2 mg</span></p>
<p><span class="Bold">NDC 0378-5446-91</span></p>
<p><span class="Bold">Tolterodine<br>Tartrate<br>Tablets<br>2 mg</span></p>
<p><span class="Bold">PHARMACIST: Dispense the accompanying<br>Patient Information Leaflet to each patient.</span></p>
<p><span class="Bold">Rx only 60 Tablets</span></p>
<p>Each film-coated tablet contains:<br>Tolterodine tartrate 2 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication<br>out of the reach of children.</span></p>
<p><span class="Bold">Store at 20Â° to 25Â°C (68Â° to 77Â°F).<br>[See USP Controlled Room<br>Temperature.]</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.<br></span>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM5446D</span></p>
<div class="Figure"><img alt="Tolterodine Tartrate Tablets 2 mg Bottle Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=304023e8-57ad-4dd7-9cf0-a4524623aa6c&amp;name=bfc370b4-6a62-44de-a353-dd59768e3133-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOLTERODINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">tolterodine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-5445</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOLTERODINE TARTRATE</strong> (TOLTERODINE) </td>
<td class="formItem">TOLTERODINE TARTRATE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;TT1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-5445-91</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-5445-69</td>
<td class="formItem">140  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0378-5445-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202641</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOLTERODINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">tolterodine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-5446</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOLTERODINE TARTRATE</strong> (TOLTERODINE) </td>
<td class="formItem">TOLTERODINE TARTRATE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;TT2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-5446-91</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-5446-69</td>
<td class="formItem">140  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0378-5446-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202641</td>
<td class="formItem">11/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bfc370b4-6a62-44de-a353-dd59768e3133</div>
<div>Set id: 304023e8-57ad-4dd7-9cf0-a4524623aa6c</div>
<div>Version: 2</div>
<div>Effective Time: 20120723</div>
</div>
</div>Â <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
